Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Boris Cheskis, Ph.D., Wyeth Pharmaceuticals: Based on the report of an investigation conducted by Wyeth Pharmaceuticals and additional analysis conducted by ORI in its oversight review, ORI found that Boris Cheskis, Ph.D., former senior scientist, Discovery Research, Women's Health, Wyeth Pharmaceuticals, engaged in research misconduct in grant applications 1 R01 DK072026-01 and 1 R01 DK072026-01A2 submitted to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH. Specifically, ORI found that: <bullet> The Respondent engaged in misconduct in science, 42 CFR 50.102, in NIDDK, NIH, grant application 1 R01 DK072026-01, "MNAR Crosstalk with Steroid Receptors," submitted to NIH on September 28, 2004, by intentionally falsifying Figures 5 and 6. <bullet> The Respondent engaged in research misconduct, 42 CFR 93.10
A formal finding of research misconduct under 42 CFR part 93 (HHS) or equivalent agency policy. The respondent was found to have engaged in fabrication, falsification, or plagiarism of research data. The federal grant funds involved are typically identified in the FR notice, along with the administrative actions (debarment, supervised research, manuscript correction or retraction requirements).